期刊文献+

卡泊三醇倍他米松软膏联合窄谱中波紫外线治疗斑块状银屑病的随机对照研究 被引量:10

Caicipotriol betamethasone ointment combined with narrow band-ultraviolet B in the treatment of plaque- type psoriasis: a randomized controlled study
原文传递
导出
摘要 目的探讨卡泊三醇倍他米松软膏联合窄谱中波紫外线(NB—UVB)治疗斑块状银屑病的疗效及安全性。方法随机、单盲平行对照、多中心临床试验,108例斑块状银屑病患者随机纳入试验组或对照组,疗程4周。对照组单纯进行NB—UVB照射;试验组NB—UVB照射方法同对照组,卡泊三醇倍他米松软膏每晚外用。治疗前、治疗2周、4周时观察疗效及安全性,治疗结束后1、2.4周进行随访。结果两组患者治疗2周后,试验组有效率15.09%,对照组有效率2.04%,总体疗效分析差异有统计学意义。治疗4周后,试验组有效率77.36%,对照组26.53%,两组差异有统计学意义(P〈0.01)。治疗前两组PASI评分比较,差异无统计学意义;治疗2周、4周以及随访1周、2周、4周时,两组PASI评分比较,差异均有统计学意义。试验组未发现不良反应,对照组有1例双小腿非皮疹部位出现疼'痛.胜红斑。两组间不良反应发生率比较,差异无统计学意义。结论卡泊三醇倍他米松软膏联合NB—UVB治疗斑块状银屑病是一种见效快、安全的治疗方法。 Objective To assess the efficacy and safety of caleipotriol betamethasone ointment combined with narrow band-ultraviolet B (NB-UVB) for the treatment of plaque-type psoriasis. Methods A randomized, single-blind, parallel-controlled, multi-center clinical trial was conducted. Totally, 108 patients with plaque-type psoriasis were randomly divided into the experiment group (treated with NB-UVB plus topical ealeipotriol betamethasone ointment once daily in the evening) and control group (treated with NB-UVB only). The treatment lasted four weeks. The safety and efficacy were evaluated at the baseline, as well as two and four weeks after the beginning of treatment. Patients were scheduled for follow-up on week 1, 2 and 4 after the end of treatment. Results The response rate was 15.09% in the experiment group and 2.04% in the control group after two-week treatment (P 〈 0.01 ), 77.36% in the experiment group and 26.53% in the control group at the end of treatment (P 〈 0.01). Psoriasis area and severity index (PASI) score was similar between the two groups at the baseline, but significantly different from week 2 to week 8 after the beginning of treatment (all P 〈 0.01 ). Adverse reaction was observed in none of these patients, except for one patient in the control group who developed painful erythema in non-lesional sites of both legs. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion Calcipotriol betamethasone ointment combined with NB-UVB is a safe and effective treatment choice for plaque-type psoriasis with rapid onset of action.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2013年第11期831-833,共3页 Chinese Journal of Dermatology
  • 相关文献

参考文献6

  • 1薛梅,江明,徐素平.窄波UVB治疗寻常型银屑病的疗效观察.中国麻风皮肤病学杂志,2005,21(12):956-958. 被引量:1
  • 2黄岚,马莉,黄琼,杨勤萍,郑志忠,朱学骏,王宝玺,顾军.钙泊三醇倍他米松软膏外用治疗寻常性银屑病的随机、双肓、对照研究[J].中华皮肤科杂志,2009,42(10):691-694. 被引量:41
  • 3吴瑞斌,顾小平,陆振中,王国利,张菊根,陆建云,余婷婷.钙泊三醇倍他米松软膏治疗寻常性银屑病临床疗效观察[J].中华皮肤科杂志,2011,44(10):748-749. 被引量:8
  • 4Kragballe K, van de Kerkhof PC. Consistency of data in six phase Ⅲ clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol, 2006, 20 (1): 39-44. 被引量:1
  • 5Archier E, Devaux S, Castela E, et al. Efficacy of psoralen UV-A therapy vs. narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol, 2012, 26 Suppl 3: 11-21. 被引量:1
  • 6Rim JH, Choe YB, Youn JI. Positive effect of using calcipotriol ointment with narrow-band ultraviolet B phototherapy in psoriatic patients. Photodermatol Photoimmunol Photomed, 2002, 18 (3): 131-134. 被引量:1

二级参考文献15

  • 1Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol, 2005, 6(6): 383-392. 被引量:1
  • 2Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Aead Dermatol, 1999, 41(3 Pt 1): 401-407. 被引量:1
  • 3Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy.J Am Acad Dermatol, 2005, 53(1 Suppl 1): S17-25. 被引量:1
  • 4Charakida A, Dadzie O, Teixeira F, et al. Calcipotriol/beta- methasone dipropionate for the treatment of psoriasis.Expert Opin Pharmacother, 2006, 7(5): 597-606. 被引量:1
  • 5Simonsen L, Hoy G, Didriksen E, et al. Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle. Drug Dev Indust Pharm, 2004, 30( 10): 1095-1102. 被引量:1
  • 6Saraceno R, Andreassi L, Ayala F, et al. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat, 2007, 18(6): 361-365. 被引量:1
  • 7Vakirlis E, Kastanis A, loannides D. Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manag, 2008, 4( 1 ): 141-148. 被引量:1
  • 8Anstey AV, Kragballe K. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol, 2006, 45(8 ): 970-975. 被引量:1
  • 9Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Derrnatol, 2006, 154(6): 1155-1160. 被引量:1
  • 10Kragballe K, van de Kerkhof PC. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Delmatol Venereol, 2006, 20 (1): 39-44. 被引量:1

共引文献42

同被引文献87

引证文献10

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部